

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
09/933,797	08/22/2001	Robert A. Sikes	9901-012	7335
20582	7590 10/02/2003		EXAMINER	
PENNIE & EDMONDS LLP			SISSON, BRADLEY L	
1667 K STRI SUITE 1000	EET NW		ART UNIT	PAPER NUMBER
WASHINGTON, DC 20006			1634	

DATE MAILED: 10/02/2003

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)				
Office Action Summary	09/933,797	SIKES ET AL.				
Office Action Summary	Examiner	Art Unit				
The MAII INC DATE of this communication and	Bradley L. Sisson	1634				
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet	with the correspondence address				
A SHORTENED STATUTORY PERIOD FOR REPLY THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply - If NO period for reply is specified above, the maximum statutory period w - Failure to reply within the set or extended period for reply will, by statute, - Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b). Status	36(a). In no event, however, may within the statutory minimum of vill apply and will expire SIX (6) N cause the application to become	a reply be timely filed thirty (30) days will be considered timely. IONTHS from the mailing date of this communication. ABANDONED (35 U.S.C. § 133).				
1) Responsive to communication(s) filed on	<u> </u>					
2a) ☐ This action is FINAL . 2b) ☐ Thi	is action is non-final.					
3) Since this application is in condition for allowa						
closed in accordance with the practice under a Disposition of Claims	Ex раπе Quayie, 1935	C.D. 11, 453 O.G. 213.				
4)⊠ Claim(s) <u>1-17 and 44</u> is/are pending in the app	olication.					
4a) Of the above claim(s) is/are withdrawn from consideration.						
5) Claim(s) is/are allowed.						
6)☐ Claim(s) is/are rejected.						
7) Claim(s) is/are objected to.						
8) Claim(s) <u>1-17 and 44</u> are subject to restriction	and/or election requirer	nent.				
Application Papers						
9) The specification is objected to by the Examiner		who Eversines				
10) The drawing(s) filed on is/are: a) acception to the	-					
Applicant may not request that any objection to the 11) The proposed drawing correction filed on						
If approved, corrected drawings are required in reply to this Office action.						
12) The oath or declaration is objected to by the Ex	_					
Priority under 35 U.S.C. §§ 119 and 120						
13) Acknowledgment is made of a claim for foreign	priority under 35 U.S.0	C. § 119(a)-(d) or (f).				
a) ☐ All b) ☐ Some * c) ☐ None of:						
1. Certified copies of the priority documents have been received.						
2. Certified copies of the priority documents have been received in Application No						
 3. Copies of the certified copies of the prior application from the International But * See the attached detailed Office action for a list 	reau (PCT Rule 17.2(a))).				
14) Acknowledgment is made of a claim for domestic	priority under 35 U.S.	C. § 119(e) (to a provisional application).				
 a) ☐ The translation of the foreign language pro 15)☐ Acknowledgment is made of a claim for domesting 						
Attachment(s)						
1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449) Paper No(s)	5) Notice	ew Summary (PTO-413) Paper No(s) of Informal Patent Application (PTO-152) .				

Application/Control Number: 09/933,797 Page 2

Art Unit: 1634

Election/Restrictions

1. Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I. Claims 1-9 and 44, drawn to polynucleotide, classified in class 536, subclass 23.1.
- II. Claims 10-11, drawn to a vector, classified in class 435, subclass 320.1; and claims 12-15, drawn to a host cell, classified in class 435, subclass 252.3.
- III. Claims 16-17, drawn to a method of producing a polypeptide urogenital sinus derived gene product, classified in class 435, subclass 69.1.

The inventions are distinct, each from the other because of the following reasons:

- 2. Inventions I, II and III are related as products and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the products can be used in a process where DNA amplification is the end result, not protein production.
- 3. Inventions I and II are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions are drawn to different compounds and a life form (claims 12-15), which have different functions and effects.
- 4. Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification, and because of their recognized divergent subject matter, restriction for examination purposes as indicated is proper.

Application/Control Number: 09/933,797

Art Unit: 1634

- 5. In the event that applicant elects the invention of Group I, Group II, or Group III, the following election of species applies.
- 6. This application contains claims directed to the following patentably distinct species of the claimed invention:
 - a. In the case of Group I, the species are each of the nucleic acids disclosed (e.g., SEO ID NO: 747, 140, 763, 778, 797, 798, 801, 803, 808, 811)
 - b. In the case of Group II, applicant is to elect a single nucleotide sequence that the vector and host cell is to comprise.
 - c. In the event of Group III being elected, applicant is to elect a single nucleic acid sequence that the host cell is to comprise.
- 7. Applicant is required under 35 U.S.C. 121 to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Currently, no claim is generic.
- 8. Applicant is advised that a reply to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.
- 9. Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

Application/Control Number: 09/933,797 Page 4

Art Unit: 1634

10. Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

- 11. Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).
- 12. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).
- 13. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Bradley L. Sisson whose telephone number is (703) 308-3978. The examiner can normally be reached on 6:30 a.m. to 5 p.m., Monday through Thursday.
- 14. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Benzion can be reached on (703) 308-1119. The fax phone number for the organization where this application or proceeding is assigned is (703) 872-9306.

Art Unit: 1634

Any inquiry of a general nature or relating to the status of this application or proceeding 15. should be directed to the receptionist whose telephone number is (703) 308-0196.

> Bradley L. Sisson **Primary Examiner**

B. L. Sisson

Art Unit 1634

BLS